3ln2

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (06:36, 19 July 2023) (edit) (undo)
 
(6 intermediate revisions not shown.)
Line 1: Line 1:
-
[[Image:3ln2.png|left|200px]]
 
-
<!--
+
==Crystal Structure of a Charge Engineered Human Lysozyme Variant==
-
The line below this paragraph, containing "STRUCTURE_3ln2", creates the "Structure Box" on the page.
+
<StructureSection load='3ln2' size='340' side='right'caption='[[3ln2]], [[Resolution|resolution]] 2.04&Aring;' scene=''>
-
You may change the PDB parameter (which sets the PDB file loaded into the applet)
+
== Structural highlights ==
-
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+
<table><tr><td colspan='2'>[[3ln2]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3LN2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3LN2 FirstGlance]. <br>
-
or leave the SCENE parameter empty for the default display.
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.037&#8491;</td></tr>
-
-->
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3ln2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3ln2 OCA], [https://pdbe.org/3ln2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3ln2 RCSB], [https://www.ebi.ac.uk/pdbsum/3ln2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3ln2 ProSAT]</span></td></tr>
-
{{STRUCTURE_3ln2| PDB=3ln2 | SCENE= }}
+
</table>
 +
== Disease ==
 +
[https://www.uniprot.org/uniprot/LYSC_HUMAN LYSC_HUMAN] Defects in LYZ are a cause of amyloidosis type 8 (AMYL8) [MIM:[https://omim.org/entry/105200 105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.<ref>PMID:8464497</ref>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/LYSC_HUMAN LYSC_HUMAN] Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents.
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Human lysozyme is a key component of the innate immune system, and recombinant forms of the enzyme represent promising leads in the search for therapeutic agents able to treat drug-resistant infections. The wild type protein, however, fails to participate effectively in clearance of certain infections due to inherent functional limitations. For example, wild type lysozymes are subject to electrostatic sequestration and inactivation by anionic biopolymers in the infected airway. A charge engineered variant of human lysozyme has recently been shown to possess improved antibacterial activity in the presence of disease associated inhibitory molecules. Here, the 2.04 A crystal structure of this variant is presented along with an analysis that provides molecular level insights into the origins of the protein's enhanced performance. The charge engineered variant's two mutated amino acids exhibit stabilizing interactions with adjacent native residues, and from a global perspective, the mutations cause no gross structural perturbations or loss of stability. Importantly, the two substitutions dramatically expand the negative electrostatic potential that, in the wild type enzyme, is restricted to a small region near the catalytic residues. The net result is a reduction in the overall strength of the engineered enzyme's electrostatic potential field, and it appears that the specific nature of this remodeled field underlies the variant's reduced susceptibility to inhibition by anionic biopolymers.
-
===Crystal Structure of a Charge Engineered Human Lysozyme Variant===
+
Crystal structure of a charge engineered human lysozyme having enhanced bactericidal activity.,Gill A, Scanlon TC, Osipovitch DC, Madden DR, Griswold KE PLoS One. 2011 Mar 7;6(3):e16788. PMID:21408218<ref>PMID:21408218</ref>
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 3ln2" style="background-color:#fffaf0;"></div>
-
<!--
+
==See Also==
-
The line below this paragraph, {{ABSTRACT_PUBMED_21408218}}, adds the Publication Abstract to the page
+
*[[Lysozyme 3D structures|Lysozyme 3D structures]]
-
(as it appears on PubMed at http://www.pubmed.gov), where 21408218 is the PubMed ID number.
+
== References ==
-
-->
+
<references/>
-
{{ABSTRACT_PUBMED_21408218}}
+
__TOC__
-
 
+
</StructureSection>
-
==About this Structure==
+
-
[[3ln2]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3LN2 OCA].
+
-
 
+
-
==Reference==
+
-
<ref group="xtra">PMID:21408218</ref><references group="xtra"/>
+
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
-
[[Category: Lysozyme]]
+
[[Category: Large Structures]]
-
[[Category: Gill, A.]]
+
[[Category: Gill A]]
-
[[Category: Griswold, K E.]]
+
[[Category: Griswold KE]]
-
[[Category: Scanlon, T C.]]
+
[[Category: Scanlon TC]]

Current revision

Crystal Structure of a Charge Engineered Human Lysozyme Variant

PDB ID 3ln2

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools